CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock	Common Stock	Additional Paid-in Capital	Common Stock to be Issued	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2021		$ 100	$ 218,762		$ (95,683)	$ 123,179
Beginning balance (in shares) at Dec. 31, 2021		99,976,253
Issuance of Series A Convertible Preferred Stock, net of issuance costs	$ 9,273					9,273
Issuance of Series A Convertible Preferred Stock, net of issuance costs (in shares)	9,566
Common stock offering, net of issuance costs		$ 1	6,783			$ 6,784
Common stock offering, net of issuance costs (in shares)		813,986
Warrant exercise (in shares)						0
Preferred stock dividends					(45)	$ (45)
Net loss					(18,183)	(18,183)
Ending balance at Mar. 31, 2022	$ 9,273	$ 101	225,545		(113,911)	121,008
Ending balance (in shares) at Mar. 31, 2022	9,566	100,790,239
Beginning balance at Dec. 31, 2022	$ 9,273	$ 145	294,810	$ (186,474)		117,754
Beginning balance (in shares) at Dec. 31, 2022	9,566	145,492,971
Common stock reacquired and exchanged for warrants		$ (12)	(12,479)			(12,491)
Common stock reacquired and exchanged for warrants (in shares)		(12,000,000)
Warrant issuance in conjunction with debt modification			16,036			16,036
Warrant offerings			14,991			14,991
Common stock offering, net of issuance costs		$ 41	26,268			26,309
Common stock offering, net of issuance costs (in shares)		40,764,706
Common stock to be issued, net of issuance costs					4,390	$ 4,390
Warrant exercise (in shares)						342,326
Convertible promissory notes converted to common stock		$ 12	4,693			$ 4,705
Convertible promissory notes converted to common stock (in shares)		11,762,956
Stock-based compensation expense and issuance of stock			876			876
Stock-based compensation expense and issuance of stock (in shares)		248,049
Net loss				(26,257)		(26,257)
Ending balance at Mar. 31, 2023	$ 9,273	$ 186	$ 345,195	$ (212,731)	$ 4,390	$ 146,313
Ending balance (in shares) at Mar. 31, 2023	9,566	186,268,682